Market Overview

Repligen Corp. (RGEN) To Outperform

Share:

According to a report released by Rodman & Renshaw, Repligen Corp.(NASDAQ: RGEN)(FREE stock trend analysis) failed to meet the specified primary end-points for the phase 3 study of RG1068. Since, RG1068 is expected to have only marginal commercial potential, Rodman & Renshaw analyst Elemer Piros, has maintained its 12-months price target of $9. Mr. Piros has also maintained the ‘Outperformer’ rating for the stock.

Phase 3 study involved baseline-controlled, single dose study enrolling 258 patients across 23 sites in USA and Canada. Although the results did not satisfy the primary endpoints, however, it was quite close to them. Even if the firm has to repeat phase 3, resulting delay is likely to have only marginal effect on company’s valuation. Commercial value of RG1038 is pegged at peak US sales of $50-75 Million.

Posted-In: Elemer Piros Rodman and RenshawUpgrades Analyst Ratings

 

Related Articles (RGEN)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
ARMKBarclaysMaintains45.0
HDDZ BankDowngrades
COGWolfe ResearchUpgrades
MLHRSidoti & Co.Maintains45.0
ICFISidoti & Co.Maintains99.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Stryker's New Share Repurchases - Analyst Blog

Jim Cramer Is Bullish On UBSI, TRA, NITE, PFE, THS, JPM, BMY